ANGO vs CNMD

For growth investors, CONMED Corporation (CNMD) is the stronger pick with 5.

2% revenue growth year-over-year, versus -3. 8% for AngioDynamics, Inc. (ANGO). CONMED Corporation (CNMD) offers the better valuation at 25. 2x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate AngioDynamics, Inc. (ANGO) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AngioDynamics, Inc.

(ANGO) delivered a total return of -53. 3%, compared to -71. 0% for CONMED Corporation (CNMD). Over 10 years, the gap is even starker: CNMD returned +6. 6% versus ANGO's -9. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AngioDynamics, Inc.

(ANGO) is the lower-risk stock at 1. 32β versus CONMED Corporation's 1. 34β — meaning CNMD is approximately 1% more volatile than ANGO relative to the S&P 500.

By revenue growth (latest reported year), CONMED Corporation (CNMD) is pulling ahead at 5.

2% versus -3. 8% for AngioDynamics, Inc. (ANGO). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, CNMD leads at 9. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CONMED Corporation (CNMD) is the more profitable company, earning 3.

4% net margin versus -11. 6% for AngioDynamics, Inc. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNMD leads at 10. 3% versus -13. 7% for ANGO. At the gross margin level — before operating expenses — ANGO leads at 53. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CNMD: 104.

8% to $78. 00.

In this comparison, CNMD (2.

1% yield) pays a dividend. ANGO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CONMED Corporation (CNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2.

1% yield). Both have compounded well over 10 years (CNMD: +6. 6%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CNMD pays a dividend while ANGO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.